Edit

LENSAR, Inc.

https://www.lensar.com/

Last activity: 27.02.2025

Active

Categories: HardwareManufacturingMedTechTechnology

Laser Refractive Cataract Surgery

Mentions

Location: United States, Florida, Orlando

Total raised: $121M

Investors 2

Date	Name	Website
-	Aisling Ca...	aislingcap...
26.12.2024	BPEA Priva...	bpea-pe.co...

Funding Rounds 3

Date	Series	Amount	Investors
02.10.2013	-	$87M	-
11.07.2012	-	$10M	-
12.03.2012	-	$24M	-

Mentions in press and media 22

Date	Title	Description
27.02.2025	LENSAR Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update	31 ALLY Robotic Cataract Laser Systems™ placed in Q4 2024, representing an 86% increase in ALLY placements in full year 2024 over 2023; Company’s total installed systems increased to approximately 385 as of December 31, 2024, representing a...
19.02.2025	LENSAR to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 27, 2025	ORLANDO, Fla., Feb. 19, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced that t...
02.01.2025	LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	ORLANDO, Fla., Jan. 02, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”) today announced that a majority of the independent members of LENSAR’s board of directors granted three newly-hired non-executive emplo...
07.11.2024	LENSAR Reports Third Quarter 2024 Results and Provides Business Update	24 ALLY Robotic Laser Cataract Systems™ placed in 3Q 2024 including 11 sales in EU and Southeast Asia; Robust backlog with 24 systems pending installation as of September 30, 2024 38% Revenue growth over third quarter 2023 and 22% Recurring...
01.11.2024	LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	ORLANDO, Fla., Nov. 01, 2024 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”) today announced that a majority of the independent members of LENSAR’s board of directors granted two newly-hired non-executive employe...
01.11.2024	LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	ORLANDO, Fla., Nov. 01, 2024 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”) today announced that a majority of the independent members of LENSAR’s board of directors granted two newly-hired non-executive employe...
31.10.2024	LENSAR to Report Third Quarter 2024 Financial Results on Thursday, November 7, 2024	ORLANDO, Fla., Oct. 31, 2024 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced that t...
01.10.2024	LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	ORLANDO, Fla., Oct. 01, 2024 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”) today announced that a majority of the independent members of LENSAR’s board of directors granted two newly-hired non-executive employe...
08.11.2021	LENSAR Reports Third Quarter 2021 Financial Results and Provides Business Update - Form 8-K	LENSAR Reports Third Quarter 2021 Financial Results and Provides Business Update Third Quarter 2021 Procedure Volumes Increase 23% over 2020 Levels Cash and Cash Equivalents of $32.3 Million reflect Cash Utilization of $2.2 Million in the Q...
15.07.2021	LENSAR : Announces In-Person Demonstrations of Its Next Generation ALLY™ System and Multiple Data Presentations at the American Society of Cataract and Refractive Surgery (ASCRS) 2021 Annual Meeting	LENSAR, Inc. (NASDAQ: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced a total of 12 abstracts highlighting LENSA...
03.03.2021	LENSAR to Hold Fourth Quarter and Full Year 2020 Financial Results and Business Update Conference Call on Wednesday, March 10, 2021	ORLANDO, Fla.--(BUSINESS WIRE)--Mar 3, 2021-- LENSAR, Inc. (NASDAQ: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announ...
04.08.2014	LensAR raises $8M for laser eye surgery	Opthalmology devices maker LensAR secured $8 million in equity funding, according to an SEC filing dated July 31, 2014. Any who needs eye surgery fast then make sure you get a good optometrist and not some random doctor. The funding round, ...
09.01.2014	LensAR closes $10M equity funding round	Orlando, Fla.-based cataract surgery technology company LensAR closed an equity funding round with $10 million raised from 14 investors, regulatory documents show. The fundraising effort, launched in December, was closed yesterday and use o...
03.10.2013	LENSAR Closes $87M Financing	LENSAR Inc., an Orlando, FL-based developer of a laser system for refractive laser-assisted cataract surgery (ReLACS), closed an $87m financing. This included a $27m private equity financing and up to $60m in debt financing. New investor PD...
02.10.2013	LensAR raises $87M for laser cataract surgery system	Orlando, Fla.-based medical device company LensAR Inc. touted $87 million in fundraising, mostly through a debt financing agreement, in support of its laser cataract surgery systems. LensAR raised $27 million in private equity financing and...
02.10.2013	Lensar Secures $87 Million in Financing to Support Market Expansion of Its Laser Cataract Surgery System	ORLANDO, FL–(Marketwired – Oct 2, 2013) – LENSAR Inc., developer of the next-generation LENSAR™ Laser System for refractive laser-assisted cataract surgery (ReLACS), today announced the closing of $27 million in private equity financing and...
02.10.2013	LENSAR Secures $27M in Equity Financing	ORLANDO, FL, Developer of the next-generation LENSAR Laser System for refractive laser-assisted cataract surgery (ReLACS), today announced the closing of $27 million in private equity financing and up to $60 million in debt financing. &g...
11.07.2012	LensAR Receives $10M Debt Facility from Oxford Finance	LensAR, Inc., an Orlando, Florida-based developer and supplier of laser and advanced 3D imaging technology for a refractive cataract surgery, has received a $10m debt facility from Oxford Finance LLC. The company intends to use the funding ...
19.03.2012	Laser cataract surgery system preps for commercial launch with $24M round	About 22 million Americans over the age of 40 have cataracts, a clouding of the eye’s natural lens. Corrective surgery usually involves making at least one incision in the eye to remove the clouded lens and replace it with a plastic or sili...
12.03.2012	LensAR Closes $24M Financing	LensAR, Inc., an Orlando, Florida-based developer of laser systems for cataract surgery, has closed a $24m financing. Backers included Aisling Capital and Florida Growth Fund (FGF). The company intends to use the capital for the first comme...
12.03.2012	LensAR Closes $24M	ORLANDO, FL, Developer of the next generation of laser systems for cataract surgery, announced the closing of a $24 million private financing, which included investments from Aisling Capital and Florida Growth Fund. >> Click here f...
-	Laser cataract surgery system preps for commercial launch with $24M round	A comprehensive laser eye surgery system that would automate manual incisions and eliminate the need for ultrasound power in cataract refractory procedures is preparing for commercial launch in the U.S., Europe and other international marke...

LENSAR, Inc.

Investors 2

Funding Rounds 3

Mentions in press and media 22

Reviews 0